SCHEMBL6538856

SCHEMBL6538856

CC(C)COC(=O)NC(C)[C]=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.49
TSHR P16473 6/20 0.41
ALDH1A1 P00352 3/20 0.41
KDM4E B2RXH2 2/20 0.41
MAPT P10636 1/20 0.41
MAPK1 P28482 1/20 0.41
HSD17B10 Q99714 1/20 0.41
HTT P42858 2/20 0.37
LMNA P02545 2/20 0.37
ALOX15 P16050 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
MAOB P27338 1/20 0.33
HSD11B1 P28845 1/20 0.32
CSNK2A2 P19784 1/20 0.32
CSNK2A1 P68400 1/20 0.32
ITGB3 P05106 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9425849 0.82 SMN1; SMN2 (0.41) SMN1; SMN2ALDH1A1MAPTMAPK1HSD17B10
SCHEMBL1999788 0.82 SMN1; SMN2 (0.41) SMN1; SMN2ALDH1A1MAPTMAPK1HSD17B10
SCHEMBL7297292 0.81 SMN1; SMN2 (0.46) SMN1; SMN2TSHRALDH1A1KDM4EMAPT
SCHEMBL7297298 0.81 SMN1; SMN2 (0.46) SMN1; SMN2TSHRALDH1A1KDM4EMAPT
SCHEMBL7766005 0.79 SMN1; SMN2 (0.45) SMN1; SMN2TSHRALDH1A1KDM4EMAPT
SCHEMBL8253529 0.79 SMN1; SMN2 (0.55) SMN1; SMN2TSHRALDH1A1KDM4EMAPT
SCHEMBL1995105 0.76
SCHEMBL1995104 0.76
SCHEMBL6539628 0.76 EPHX1 (0.46) SMN1; SMN2ALDH1A1MAPK1L3MBTL1
SCHEMBL7612731 0.76 EPHX1 (0.46) SMN1; SMN2ALDH1A1MAPK1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6812235-B2 2-ACYLAMINO- BETA -ALANINE DERIVATIVES AND A PHARMACEUTICALLY ACCEPTABLE SALT, USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-02 US disclosed
US-20030018193-A1 Beta-alanine derivatives and their use as receptor anatgonists ASTELLAS PHARMA INC. (JP) 2003-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018193-A1 Beta-alanine derivatives and their use as receptor anatgonists ARRB1, ADRB1, GLRB SMN1; SMN2 2439/4885TSHR 689/4885ALDH1A1 578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.